drugset / Trial / NCT02786732
Study to Evaluate Broadlumab vs Placebo and Ustekinumab
RandomizedSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the efficacy and safety of Induction and Maintenance Regimens of Brodalumab compared with Placebo and Ustekinumab in subjects with moderate to severe plaque psoriasis.
Timeline
- Start
- 2012-08
- Primary completion
- 2017-06
- Completion
- 2017-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brodalumab | Monoclonal antibody | 140 mg | Subcutaneous |
| Subject | Brodalumab | Monoclonal antibody | 210 mg | Subcutaneous |
| Comparator | Ustekinumab | Monoclonal antibody | 45 mg | Subcutaneous |
| Comparator | Ustekinumab | Monoclonal antibody | 90 mg | Subcutaneous |